[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 4 sources · 15 days · First seen · Last updated

Brazilian pharmaceutical industry investment and growth

Overview

The Brazilian pharmaceutical and wellness sectors are seeing significant investment and growth. In August 2026, Arese Pharma secured R$ 20 million in BNDES financing to enhance its manufacturing unit in Valinhos, São Paulo. This funding is directed toward research, development, and innovation to produce antidepressants and anti-inflammatories not currently available in Brazil, as well as creating new administration methods for pediatric and geriatric patients.

By September 2026, the market showed broader expansion, with the self-care and wellness segment reaching R$ 27.7 billion. During this period, the Italian company Chiesi announced a R$ 124 million investment to expand its Santana de Parnaíba facility. This expansion aims to increase production capacity for asthma and COPD inhalers by nearly 67% while utilizing new propellants to reduce carbon footprints.

Entities

Brazil · BNDES · Close-Up International · Arese Pharma · Alanac

Timeline

  1. 4 days ago

    [BUSINESS] 2 sources
    Brazil pharmaceutical market grows as Chiesi invests R$ 124 million

    Brazil's wellness market has reached R$ 27.7 billion, while Italian firm Chiesi is investing R$ 124 million to expand its Brazilian factory and produce low-carbon asthma inhalers.

  2. 18 days ago

    [BUSINESS] 4 sources
    Arese Pharma receives R$ 20 million in BNDES financing

    Arese Pharma secured R$ 20 million from BNDES to develop new antidepressants and anti-inflammatories in Brazil, aiming to introduce active ingredients not currently available in the domestic market.

Sources

collegeaccounting.com · folhadevalinhos.com.br · meioemensagem.com.br · panoramafarmaceutico.com.br